Figure 6A demonstrates that ADM injection increased the serum levels of total TGF-β when compared with control mice, reinforcing the idea that TGF-β overproduction is associated with glomerulosclerosis [25]. Unexpectedly, we found that GSL-1 treatment further elevated the serum levels of TGF-β. qPCR analysis of kidney tissue revealed that the induction of TGF-β mRNA exactly reflected the serum findings. The ADM group showed higher levels of TGF-β transcripts than the control animals but lower than those found in GSL-1 mice (Figure 6B). The gene discussed is TGFB1; the disease is glomerulosclerosis.